NEW YORK, NY / ACCESSWIRE / April 3, 2020 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss, you can request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
PharmaCielo Ltd. (OTCQX:PCLOF)
Class Period: June 21, 2019 - March 2, 2020
Deadline: May 5, 2020
For more info: www.bgandg.com/pclof
The Complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements and/or failed to disclose that: (1) PharmaCielo engaged in an undisclosed related party transactions with General Extract LLC; (2) PharmaCielo engaged in misleading transactions and loans with General Extract LLC and XPhyto Therapeutics Corp.; (3) PharmaCielo's Research Technology and Processing Centre was never on-schedule and is delayed; (4) the Rionegro facility is located on a floodplain and contaminated with mold and pesticides from its previous tenants; (5) PharmaCielo's Cauca Department land has never been utilized by the Company and is idle; and (6) as a result, Defendants' public statements were materially false and/or misleading at all relevant times.
Tilray, Inc. (NASDAQ:TLRY)
Class Period: January 15, 2019 - March 2, 2020
Deadline: May 5, 2020
For more info: www.bgandg.com/tlry
The Complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements and/or failed to disclose that: (1) the purported advantages of the ABG Agreement were significantly overstated; (2) the underperformance of the ABG Agreement would foreseeably have a significant impact on the Company's financial results; and (3) as a result, the Company's public statements were materially false and misleading at all relevant times.
Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | [email protected]
SOURCE: Bronstein, Gewirtz & Grossman, LLC